Investigating how CD44 signaling affects glioblastoma and immune response
Targeting CD44 signaling in regulating glioblastoma stemness and immune response
This study is looking at ways to make treatments for glioblastoma, a tough type of brain tumor, work better by focusing on a specific protein called CD44, which helps us understand how the tumor interacts with the immune system and other cells, with the hope of finding new strategies that could improve survival and quality of life for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-10851941 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor, and aims to improve treatment outcomes by targeting CD44 signaling. The study explores how CD44 interacts with the tumor microenvironment and immune cells, which may influence the effectiveness of oncolytic viral therapy. By understanding these interactions, the research seeks to enhance the efficacy of existing therapies, particularly those involving oncolytic herpes simplex viruses. Patients may benefit from new treatment strategies that could improve survival rates and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking innovative treatment options.
Not a fit: Patients with other types of brain tumors or those who are not eligible for glioblastoma treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving patient survival and quality of life.
How similar studies have performed: Previous research has shown promising results with oncolytic viral therapies in treating glioblastoma, indicating that this approach has potential for success.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Hong, Bangxing B — Augusta University
- Study coordinator: Hong, Bangxing B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.